Figure 1.

Demonstrates the trial schema from screening to the final assessment at 12 months post-treatment. AEs, adverse events; FDG, fluorodeoxyglucose; PET, positron emission tomography; RT, radiation therapy; VMAT, Volumetric Modulated Arc Therapy; V/Q, ventilation and perfusion.